168 related articles for article (PubMed ID: 19801173)
1. Genome integrity: linking pluripotency and tumorgenicity.
Deng W; Xu Y
Trends Genet; 2009 Oct; 25(10):425-7. PubMed ID: 19801173
[TBL] [Abstract][Full Text] [Related]
2. p53 switches off pluripotency on differentiation.
Lin T; Lin Y
Stem Cell Res Ther; 2017 Feb; 8(1):44. PubMed ID: 28241890
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states.
Neveu P; Kye MJ; Qi S; Buchholz DE; Clegg DO; Sahin M; Park IH; Kim KS; Daley GQ; Kornblum HI; Shraiman BI; Kosik KS
Cell Stem Cell; 2010 Dec; 7(6):671-81. PubMed ID: 21112562
[TBL] [Abstract][Full Text] [Related]
4. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
5. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells.
Chang G; Miao YL; Zhang Y; Liu S; Kou Z; Ding J; Chen DY; Sun QY; Gao S
PLoS One; 2010 Apr; 5(4):e10320. PubMed ID: 20436676
[TBL] [Abstract][Full Text] [Related]
6. The genomic stability of induced pluripotent stem cells.
Chen Z; Zhao T; Xu Y
Protein Cell; 2012 Apr; 3(4):271-7. PubMed ID: 22528751
[TBL] [Abstract][Full Text] [Related]
7. Induced pluripotent stem cells and senescence: learning the biology to improve the technology.
Banito A; Gil J
EMBO Rep; 2010 May; 11(5):353-9. PubMed ID: 20379220
[TBL] [Abstract][Full Text] [Related]
8. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.
Vazquez-Martin A; Vellon L; Quirós PM; Cufí S; Ruiz de Galarreta E; Oliveras-Ferraros C; Martin AG; Martin-Castillo B; López-Otín C; Menendez JA
Cell Cycle; 2012 Mar; 11(5):974-89. PubMed ID: 22333578
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide overcomes pluripotency deficits and reprogramming barriers.
Son MJ; Son MY; Seol B; Kim MJ; Yoo CH; Han MK; Cho YS
Stem Cells; 2013 Jun; 31(6):1121-35. PubMed ID: 23526681
[TBL] [Abstract][Full Text] [Related]
10. The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells.
Mishra S; Kacin E; Stamatiadis P; Franck S; Van der Jeught M; Mertes H; Pennings G; De Sutter P; Sermon K; Heindryckx B; Geens M
Mol Hum Reprod; 2018 Apr; 24(4):173-184. PubMed ID: 29471503
[TBL] [Abstract][Full Text] [Related]
11. Elite model for the generation of induced pluripotent cancer cells (iPCs).
Lai J; Kong CM; Mahalingam D; Xie X; Wang X
PLoS One; 2013; 8(2):e56702. PubMed ID: 23418593
[TBL] [Abstract][Full Text] [Related]
12. Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma.
Lake BB; Fink J; Klemetsaune L; Fu X; Jeffers JR; Zambetti GP; Xu Y
Stem Cells; 2012 May; 30(5):888-97. PubMed ID: 22311782
[TBL] [Abstract][Full Text] [Related]
13. Trib2 regulates the pluripotency of embryonic stem cells and enhances reprogramming efficiency.
Do EK; Park JK; Cheon HC; Kwon YW; Heo SC; Choi EJ; Seo JK; Jang IH; Lee SC; Kim JH
Exp Mol Med; 2017 Nov; 49(11):e401. PubMed ID: 29170476
[TBL] [Abstract][Full Text] [Related]
14. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells.
Mosca E; Cocola C; Sabour D; Pelucchi P; Bertalot G; Palumbo O; Carella M; Götte M; Schöler HR; Reinbold R; Zucchi I; Milanesi L
In Silico Biol; 2010; 10(5-6):207-21. PubMed ID: 22430355
[TBL] [Abstract][Full Text] [Related]
15. Linking Pluripotency Reprogramming and Cancer.
Iglesias JM; Gumuzio J; Martin AG
Stem Cells Transl Med; 2017 Feb; 6(2):335-339. PubMed ID: 28191771
[TBL] [Abstract][Full Text] [Related]
16. Micro-management of pluripotent stem cells.
Guo WT; Wang XW; Wang Y
Protein Cell; 2014 Jan; 5(1):36-47. PubMed ID: 24470117
[TBL] [Abstract][Full Text] [Related]
17. The miR-302-Mediated Induction of Pluripotent Stem Cells (iPSC): Multiple Synergistic Reprogramming Mechanisms.
Ying SY; Fang W; Lin SL
Methods Mol Biol; 2018; 1733():283-304. PubMed ID: 29435941
[TBL] [Abstract][Full Text] [Related]
18. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
19. Redox and Epigenetics in Human Pluripotent Stem Cells Differentiation.
Giallongo S; Rehakova D; Raffaele M; Lo Re O; Koutna I; Vinciguerra M
Antioxid Redox Signal; 2021 Feb; 34(4):335-349. PubMed ID: 32567336
[No Abstract] [Full Text] [Related]
20. The emerging role of p53 in stem cells.
Bonizzi G; Cicalese A; Insinga A; Pelicci PG
Trends Mol Med; 2012 Jan; 18(1):6-12. PubMed ID: 21907001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
